Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

[EX Q]: Instead, he said, he met them on their front lawn, where he popped the girl’s joint back in. “It is a very easy thing to do, but it made a huge difference for them,” he said. Gulbransen has had to rethink how he runs his pediatric practice on Long Island since the coronavirus crisis started. “We’re in the heart of the storm,” said Gulbransen. His practice remains open and now also welcomes some non-pediatric patients who have had trouble being seen by a doctor. He said his practice has been physically rearranged to keep sick patients away from those who are well. Other recent adjustments include doing telemedicine, although he is unsure how insurance reimbursements will work with such consultations. He said he was worried about his pediatric patients picking up on their parents’ anxieties, as well as the health and financial welfare of his staff. “The anxiety level is palpable,” said Gulbransen. “But it’s a privilege,” he said, adding, “you’re here for your patients. You gotta push and do whatever it takes.”  New York state, the epicenter of the pandemic in the United States, had a coronavirus death toll exceeding 10,000 as of Tuesday, out of more than 28,000 across the country. The disease looks different in children than it tends to with adults, said Gulbransen. “We had a 6-week-old with COVID, and really (the infant had) no other symptom than a runny nose,” said Gulbransen. He has also treated “quite a few toddlers and plenty of schoolage children,” who were all doing well. Cases of the illness involving children are “dwarfed by adult cases, although some of the (child) cases can be quite severe,” according to Dr. Lorry Rubin, director of pediatric infectious diseases at Cohen Children’s Medical Center, part of the Northwell Health network. Sometimes previously healthy children, often adolescents, develop pneumonia “and that can be severe and possibly lead to them needing oxygen or ventilatory support,” Rubin said. Still, most pediatric COVID-19 patients do well. Rubin said he was aware of only one child who had died, who also had a terminal congenital illness. Among infants under 60 days old in whom COVID had been detected, “all of them have done quite well,” he added. “The frequency of pediatric illness requiring hospitalization is low,” Rubin said. “No question, it’s not as bad in children and less common than in adults.”  But with New York’s healthcare system at full throttle treating coronavirus patients, Gulbransen wants to take no risks. His motto is: “Whatever you do, don’t send someone from this office to the ER.”
[EX A]: 'Don't go to the ER': how a New York pediatrician is dealing with the coronavirus outbreak.

[EX Q]: After hearing about a few more episodes Breckenridge had, Berger suggested she get a gate for the top of the stairs, in case Breckenridge were to fall. She then asked Breckenridge if she had set up Alexa, the virtual assistant developed by Amazon, which she had. They then discussed different exercises they had gone over in the past. Berger asked the patient about her arm mobility — asking her to lift her arm — and stability, prompting her to stand up without holding on to anything. After about a 30-minute session, they said their goodbyes and logged off their computers. Berger, a physical therapist, certified dementia specialist and owner of Rehab Smarter, conducted the entire session online. Rehab Smarter is a local telehealth business that provides comprehensive rehabilitation services to patients over the internet. “This has been a saving grace for me,” Breckenridge said. “It’s not because I don’t want to go to the doctor’s office. It’s because I can’t get to them. If I could, I would be there.” The Brunswick resident turned to telehealth services due to her decreased mobility. She is, for the most part, homebound due to having multiple seizures a day. While she has online sessions with doctors, they still recommend that she come into the office at times to run certain tests and other functions that physicians are not yet capable of completing online. She works with Berger through online sessions about twice a week. Working with her is “completely the same” as if she were sitting with Berger face to-face. “Just because you’re stuck at home doesn’t mean that you can’t get the help that you need,” she said. “People just need to find the help that they need, and sometimes it’s on the internet.” Berger started Rehab Smarter about 18 months ago. She conducts sessions with her patients through an online portal where she can email with them directly, upload videos and add notes for their benefit. Everything is Health Insurance Portability and Accountability Act, or HIPAA, compliant. She typically doesn’t do a face-to-face assessment with the patient, but she has gone in-home to see the setup and suggested any modifications to help the patient with mobility. She may also do an initial assessment and meet with the caregiver, if there is one, and ask what the patient’s goals are. “Most of what clinicians do is educate and teach the client how to take care of themselves,” she said. She demonstrates different exercises with her patients online and, with her expertise, can detect muscle strength and functionality by just observing them perform simple tasks. “You can test cognition over the internet, you can test sensation,” she said. “You can’t listen to the heart without special equipment, but that exists.” Her average client has COPD, heart failure, diabetes, kidney disease, arthritis, high blood pressure and other conditions, all at once. They turn to telehealth because it’s difficult for them to get out of the home and go to a doctor’s office, although they sometimes do so. “It’s not really home care,” she said. “It’s not really outpatient. It’s a platform for clients that either have maxed out their benefits through traditional means or have prevention and wellness issues that will not be covered. It’s another opportunity for people.” Telehealth can be beneficial to the healthcare provider as well. When Berger provides home care through a company she works for, she can see up to six clients a day and then has hours of paperwork to complete, for insurance purposes. Through virtual care, she can see up to 12 patients with minimal paperwork. Her telehealth service is not covered under insurance, which cuts out a lot of the paperwork. A session can range from $80 to $200. With telehealth, a patient is not limited to one doctor. If Berger finds that a patient needs care in an area in which she’s not an expert, she can consult with a doctor across the country to get the patient the care they need. “So you can now get care by anybody who’s appropriate, wherever you are, at least to a point that you could not have gotten before,” she said. But even with the internet playing such a vital role in the future of medicine, there are still many limitations to telehealth. “You can’t touch a patient,” Berger said. “If you have an abdominal problem and your physician is palpitating your stomach to feel for tension and different things, you can’t do that (over the internet). Blood tests and physical surgeries also can’t be done, at this point in time at least.” Frederick Memorial Hospital is also making headway in telehealth services. The Chronic Care Management Program gives patients tablets, blood pressure monitors, a pulse oximeter and a scale to detect their vitals in the comfort of their own home. They consult with a nurse on the team once a week by phone. By the end of the summer, they plan to have video conferencing, according to Lisa Hogan, a nurse at FMH and the team lead for both the Chronic Care Management and telemonitoring programs. The program took off in 2017 and started with 30 monitors for in-home patients. Today it has 203 in the community. Up to 200 more monitors will be added in 2020. There is already a waiting list to be a part of the program. This past winter, the hospital also launched a separate Virtual Visit Program through Monocacy Health Partners, the hospital’s own physician group. The program is for employees and primary care patients of MHP, according to Alex Nason, director of IT innovation at FMH. Through a series of questions, primary care providers can assess ailments such as upper respiratory infections, flu, cold, rash and pink eye. Although physicians can make diagnoses and write prescriptions after conducting a telehealth session, about 20 percent of the time the provider decides that they would like to see the patient in person. Through these efforts, FMH saw an 84 percent reduction in readmission rates and a 56 percent reduction in emergency room visits in 2018, according to Hogan. “Telehealth as technology has become easier to use, less expensive and more accepted. And the clinical validation is there as more and more parts of health care are embracing it,” Nason said. “I think as the technology advances, the research continues to accrue validation and the economics of healthcare continue to evolve, we’re seeing more and more movement, acceptance and options of telehealth because the stars are starting to align.” ___ Information from: The Frederick (Md.) News-Post, http://www.fredericknewspost.com
[EX A]: Telehealth rises as medium increases in validity.

[EX Q]: The news is a boost for the Spanish biotech company, which  already sells Yondelis as a treatment for soft tissue sarcoma,  a rare disease, and now hopes to address a much bigger  commercial opportunity. Bradley Monk, an oncologist from the University of  California Irvine Medical Center who led a Phase III trial of  the drug, said Yondelis could be added to a short list of  active drug therapies for recurrent ovarian cancer. “These are exciting results because positive trials in  recurrent ovarian cancer are rare and have almost always led to  federally approved treatments,” Monk said in a statement. “This treatment undoubtedly will be evaluated carefully by  the U.S. Food and Drug Administration and, if approved, will  give women with ovarian cancer another much-needed option.”    Zeltia’s drug, which it is developing with Johnson &  Johnson, is unusual in that it is a synthetic version of a  compound isolated from a type of sea squirt, a tubular marine  animal. It works by binding to the DNA of cancer cells and  blocking their ability to multiply. At 1445 GMT, Zeltia shares were down 5.4 percent at 5.43  euros, regaining ground after a low of 4.99 euros, while  Spain’s IBEX-35 blue chip index dropped 4.1 percent. “The stock’s had a good run. This news is already in the  price,” a Madrid-based trader said. The Spanish company had already announced that Yondelis,  its first product to reach the market, had shown positive  results in the pivotal trial. But the actual results of the study, involving 672 women  whose ovarian cancer had progressed after first-line treatment,  were only disclosed at the annual meeting of the European  Society of Medical Oncology (ESMO) in Stockholm. Monk said the results showed those women given a  combination of Yondelis and Johnson & Johnson’s chemotherapy  drug Doxil had no progression of their cancer for an average of  7.3 months, against 5.8 months for women treated only with  Doxil. In the case of women who had relapsed more than six months  after getting first-line therapy, the median progression-free  time was 9.2 months with Yondelis versus 7.5 months. In common with other anti-cancer agents, this suggests  Yondelis is most active in patients who have gone a long time  since receiving initial chemotherapy treatment. Zeltia plans to submit Yondelis for approval in Europe in  the fourth quarter of this year. Johnson & Johnson is expected  to file in the United States by the end of the year as well. The Spanish group has previously estimated that peak sales  of Yondelis for ovarian cancer could be around 300 million  euros ($420 million) in the European Union alone. Sales of the drug as a treatment for soft tissue sarcoma  are forecast to be about 30 million euros this year. Yondelis, whose generic name is trabectedin, is currently  approved for soft tissue sarcoma in Europe but not the U.S. The product is also being studied in smaller, Phase II  trials for prostate, breast and childhood cancers.
[EX A]:
Zeltia drug delays progression of ovarian cancer.